Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
MENLO PARK, Calif., Oct. 25, 2017 -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2017, on Wednesday, November 1, 2017, after the market close. Geron’s management will also host a conference call for analysts and investors on Wednesday, November 1, 2017, at 4:30 p.m. Eastern Time to discuss the company’s third quarter results and recent events.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 1056465. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at https://edge.media-server.com/m6/p/25tyxgih or at www.geron.com on the Investors pages, under Events. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through December 1, 2017.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
[email protected]
[email protected]
